Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
In urgent need of financial assistance? Find out where to locate immediate financial help to address your needs.
23,157 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Investors are flocking to renewable energy stocks as policy support and expanding clean-energy projects push the sect...
A newly launched dividend strategy ETF seeks to offer both a solid income stream and rising dividends, challenging th...
Value stocks are regaining ground in May as investors rotate from growth; the VLUE, AVUV, and VBR trio are delivering...
Magnolia (MGY) is delivering a pivotal Q1 2026 performance that tests the durability of its business model. This arti...
As BTC prices wobble, bitcoin miners using bear keys pivot to AI compute. A SpaceX Colossus 1 deal with Anthropic sig...
When markets get choppy, consumer staples often become a safe harbor. This article compares Vanguard VDC and State St...
Wolfspeed has bounced on recent news, but deep profitability and liquidity issues linger. This guide breaks down the ...
A recent SEC filing shows Marshall Investment Management adding a sizable stake to the TCW Flexible Income ETF (FLXR)...
This article breaks down Rekor’s Q1 2026 earnings call in plain English. Learn what the numbers mean for the rekor (r...
A coalition of chefs and tech-minded entrepreneurs is moving to scale Japan-inspired fine dining from Arkansas to the...
Amazon is betting big on hardware to power AI at scale. This article explains how amazon's chips driving growth in AI...